The discussion of prophylactic therapy in haemophilia is largely focused on joint outcomes. The impact of prophylactic therapy on intracranial haemorrhage (ICH) is less known. This study aimed to analyse ICH in children with haemophilia, with a focus on different prophylaxis regimens and sequelae of ICH. We conducted a multicentre retrospective and prospective study that included 33 haemophilia centres from 20 countries. Inclusion criteria were children and adolescents born between 1993 and 2014, with severe haemophilia A or B without inhibitors. Participants were categorized by prophylaxis regimen: full, partial or none, based on dose and dose frequency of regular infusions. The cohort study included 1515 children: 29 cases of ICH over 8038 patient years were reported. The incidence of ICH in the prophylaxis group, 0Á00033 cases of ICH/patient year, was significantly lower compared to the no prophylaxis group, 0Á017 cases of ICH/patient year (RR 50Á06; P < 0Á001) and the partial prophylaxis group, 0Á0050 cases of ICH/patient year (RR 14Á92; P = 0Á007). In the on-demand-group, 8% (2/24) children with ICH died and 33% had long-term sequelae, including intellectual and behavioural problems, paresis and epilepsy. Children on regular, frequent prophylaxis have a low risk of ICH compared to those using non-frequent or no prophylaxis.
Intracranial haemorrhage (ICH) is one of the major bleeding complications in haemophilia; it is potentially life threatening and may result in significant long-term morbidity. In Sweden, ICH accounted for one-third of all deaths in haemophilia before the era of prophylaxis (Larsson & Wiechel, 1983) . Following the development of cryoprecipitate, plasma-derived concentrates and recombinant factor concentrates, the mortality rate and incidence rate due to ICH dropped. The largest cohort study, the United States (US) Universal Data Collection (UDC) study, which included over 10 000 patients with haemophilia A (HA) and B (HB) and who were followed from 1 to 12 years, reported an incidence of ICH of 1Á9%, a frequency of 390 events/10 5 patient years and an ICH mortality rate of 19Á6% (Witmer et al, 2011) . Other studies investigating mortality in patients with haemophilia treated on demand show similar results with a mortality rate around 20% for ICH (de Tezanos Pinto et al, 1992; Chorba et al, 1994; Triemstra et al, 1995; Quinones-Hinojosa et al, 2003) . Recent studies have reported an incidence of ICH in haemophilia of 290-796 per 10 5 patient years, affecting around 3-10% of all patients (Ljung, 2008; Witmer et al, 2011) .
Corresponding rates for males in the otherwise healthy population were found to be 13Á9 and 38Á6 ICH events per 10 5 patient years in two investigations (Nilsson et al, 2000; Giroud et al, 2001) . In a large California cohort of 2Á3 million children, spontaneous ICH in the otherwise healthy population was found to be usually caused by cerebral aneurysm with an overall incidence of 1Á4 per 10 5 person-years (Jordan et al, 2009) . When comparing these numbers, ICH is 20-50 times more common in persons with haemophilia treated on demand compared to the non-haemophilic general population. The risk of ICH varies with the severity of haemophilia, with children with severe haemophilia (factor level <1%) at highest risk, both from spontaneous and traumatic ICH (Andes et al, 1984; Witmer et al, 2011) . In recent studies, approximately 50% of ICH cases in patients with severe haemophilia were reported to be spontaneous with the remaining cases being trauma-induced (Antunes et al, 2003; Stieltjes et al, 2005; Zanon et al, 2012) . The ICH rate after identified head trauma is reported to be 2-16%. There is evidence that, even after minor head trauma, there is an increased risk of developing ICH (Dietrich et al, 1994; Witmer et al, 2007; Lee Intracranial (Witmer et al, 2011) . The consequences of an ICH can be significant. A high frequency of sequelae has been observed in many series with a wide variety of neurological problems, ranging from executive function problems to seizures, in ICH survivors (Lutschg & Vassella, 1981; Klinge et al, 1999; Kulkarni & Lusher, 1999; Morales et al, 2013) . The risk for long-term sequelae is reported to be approximately 50-60% (de Tezanos Pinto et al, 1992; Stieltjes et al, 2005) . This is particularly relevant for the paediatric population in whom impairment and disability can remain with the child throughout their life, negatively impacting quality of life.
Based on the results of three randomized clinical trials and expert consensus, which resulted in guidelines from the World Federation of Haemophilia (WFH) and the World Health Organization (WHO), prophylactic replacement of FVIII/IX is regarded as the optimal treatment regimen for children and adults with severe haemophilia (Berntorp et al, 1995; Manco-Johnson et al, 2007 Gringeri et al, 2011; Srivastava et al, 2013) . The rationale for prophylactic treatment is to prevent bleeding events and reported outcomes have largely focused on joint bleeds and subsequent arthropathy (Nilsson et al, 1992; Richards et al, 2010; Manco-Johnson et al, 2013; Giangrande et al, 2014) . A wide variety of dosing schedules are currently employed for prophylaxis, generally ranging in dose from 15 to 50 iu/kg and a frequency from daily or every other day to once weekly (Feldman et al, 2006; Ljung & Gretenkort Andersson, 2015) . Some regimens are monitored to maintain a pre-specified trough factor activity level while others allow factor VIII or IX levels to be undetectable for variable durations between doses. The merits of various regimens have been evaluated for joint outcomes but not for risk of ICH, which is the focus of this study.
Furthermore, most studies investigating ICH in haemophilia were performed in patients using on-demand or a mixture of treatment regimens, and therefore cannot discriminate between treatment regimens and the specific effect of prophylaxis on this outcome. The University of the District of Columbia (UDC) study found a significant reduction in rates of ICH, with an odds ratio of about 0Á5, was associated with the use of any continuous prophylaxis administered at least once weekly excluding patients who were positive for HIV or an inhibitory antibody (Witmer et al, 2011) . Another large US population analysis performed using the Paediatric Hospital Information System (PHIS), that included 8325 hospital admissions for 3133 children with haemophilia, found that ICH was diagnosed in 3Á3% of all hospitalizations of children with haemophilia at a median age of 2 years; the mortality rate in these young children with haemophilia and ICH was 6/236 (2Á5%) representing an almost 90% reduction from earlier reports (Witmer, 2015) , however no distinction between different prophylaxis schedules was performed.
The objectives of the present study were: to determine the incidence -both spontaneous and traumatic -of ICH in children with severe haemophilia on conventional prophylactic treatment versus less intensive prophylaxis versus ondemand treatment; and to investigate whether sequelae after ICH were less frequent in children on prophylaxis at the time of ICH than in those not on prophylaxis. Furthermore, typical symptoms and sequelae following ICH were evaluated.
Materials and methods

Study group
The investigative group consisted of 33 centres, including 28 participating in the European Paediatric Network for Haemophilia Management (PedNet; https://www.pednet.eu/), and/or the International Network of Paediatric Haemophilia (INPH) and five other collaborators (Table I) . Centre requirements included on-going research, closely followed patient populations and availability of comprehensive medical records.
Inclusion criteria
The study was started March 2011 and closed June 2015. Children and young adults born between 1 January 1993 and 31 December 2014 with severe HA or HB (FVIII/IX < 1%) without measurable inhibitor for the last 5 years, were eligible for inclusion into this cohort study in this time period. All patients fulfilling the inclusion criteria at the participating centres were included, whether or not they had an ICH during the study period. The treatment of all included patients was stratified into three groups: Conventional prophylaxis versus less intense prophylaxis versus on-demand treatment. For HA and HB, conventional prophylaxis -designated 0 full prophylaxis group' -was defined as treatment regularly two times per week with a dose above 20 iu/kg or three times per week or more with no dose restrictions. The definition for less intense prophylaxis -named as 'partial prophylaxis group' -was treatment at least once per week with no dose restrictions or twice per week with dosing <20 iu/week. For either HA and HB, on-demand treatment -designated 'no prophylaxis group' -was defined as irregular treatment or treatment less often than once per week. None of the children utilized extended half-life factor products that require less frequent infusions for full prophylaxis. All episodes of ICH were diagnosed either by computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound.
Study design
The study consisted of a mandatory 5-year retrospective data extraction as well as a prospective observation of up to 4 years for the included patients. Each centre secured required Ethics approval. Data were entered into a webbased case report form (CRF) and a follow-up report was collected annually. The data were coded and stored in compliance with the Swedish Personal Data Act (PDA, designated PUL in Swedish) at the Paediatric Clinic, Sk ane University Hospital Malm€ o. All clinical, laboratory and imaging decisions were made by the treating haematologists using local standards of care and physician preference. The CRF registered the patient's birth year, date of diagnosis and mode of treatment (as defined above), and history of ICH prior to the retrospective data period, ICH during the 5-year retrospective data extraction and ICH during the prospective observation. For each episode of ICH, data collected included ICH imaging technique, preceding trauma, and estimation of factor (FV)III/IX concentrations at the time of ICH and treatment at the time of the ICH was recorded. Neurological signs and symptoms were captured in the CRF as well as any sequelae of ICH.
Statistical methods
The incidence of ICH in the three different treatment groups was compared by exact Poisson-test resulting in odds ratios and confidence intervals. All analysis was performed using SPSS and R (Fleiss et al, 2013) . A P-value of <0Á05 was considered to be significant. Patient years in the different treatment groups were counted from date of diagnosis of haemophilia and after the neonatal period (28 days after birth). The age distribution was calculated under the assumption that reported on-demand months are followed by partial prophylaxis and full prophylaxis.
Results
A total of 1515 patients from 33 centres were included in the study, which resulted in 8692 patient years in total, 5997 for the 'full prophylaxis group', 603 for the 'partial prophylaxis group' and 2092 for the 'no prophylaxis group'. Haemophilia A accounted for 82Á5% of included patients and remaining 17Á5% had HB. The median age at inclusion was 8Á9 years (mean 9Á4 years, range 0Á2-22Á3) (Table II) .
Sixty cases of ICH were reported. Of these, 55 occurred in patients on no prophylaxis or in those who were not yet diagnosed with a bleeding disorder, three in patients on partial prophylaxis, and two in patients on full prophylaxis. In the further analysis, with the aim to study the protective effect of prophylaxis, we excluded 15 ICH cases where the diagnosis of haemophilia had not been made at the time of the ICH and all patient years were counted from date of diagnosis. In addition, cases of ICH diagnosed during the neonatal period -which was defined as ICH during the first 28 days after birth -and four cases with a second ICH were excluded which resulted in 1438 patient years in the no prophylaxis group. This resulted in 29 cases of ICH in patients beyond the neonatal period with a known diagnosis of haemophilia. The overall incidence was 0Á7 ICH/100 patient years.
Patients on no prophylaxis had an incidence of 1Á7 ICH/ 100 patient years with a relative risk (RR) of 50Á06 compared to the 'full prophylaxis group' (P < 0Á001). The incidence for patients in the 'full prophylaxis group' was 0Á033 ICH/100 patient years. There was also a significant difference (RR 3Á35, P = 0Á035) in patients treated in the 'no prophylaxis group' compared with 'partial prophylaxis' patients, that had an incidence of 0Á50 ICH/100 patient years. When comparing the 'partial prophylaxis group' with the 'full prophylaxis group' the RR was 14Á92 (P = 0Á007) (Table III) . Because centres were recruited worldwide with different cultures and varying financial resources, we recalculated the data excluding centres in emerging countries and found consistent results (data not shown). Retrospective versus prospective part of the study
The retrospective part of the study accounted for 6781 patient years while the prospective part added 1911 patient years. The median follow-up time per patient including the retrospective and prospective part was 5Á7 years (range 1Á1-8Á0). As the incidences of ICH in the treatment groups did not differ statistically between the retrospective and prospective subgroups, they were kept together in the analysis (Table IV) .
Haemophilia A versus haemophilia B
In the 'no prophylaxis group', the rate for ICH in HA was 2Á29 ICH/100 patient years, which was similar to that of HB (2Á14 ICH/100 patient years) (P = 1Á01). The 'partial prophylaxis group' included a total of three ICH l (3/603 patient years), all of which were HA. Both cases of ICH in the 'full prophylaxis group' (2/2092) were HA. Due to these low numbers no further calculation was possible.
Age distribution
A total of 20 out of 29 cases of ICH (69%) occurred in the first 5 years of life in children treated on-demand (neonatal period excluded). Under the assumption that reported ondemand months are followed by partial prophylaxis and full prophylaxis, we calculated patient years on-demand, on partial prophylaxis and full prophylaxis for each age group (Table IV) . Approximately the same incidences as for children treated on-demand in the whole study population, could be found in the different age groups in the 'ondemand group' with a tendency to higher incidences at lower age but without statistical significance, e.g. age group 1-2 years compared to age group 2-3 years (P = 0Á574). Also, when combining age groups to age group 0 to <3 years and comparing to age group 3 to <6 years, no statistical significance could be shown (P = 0Á242) ( Table V) .
Spontaneous and trauma-induced ICH
In the 'no prophylaxis group', no information about spontaneous or traumatic ICH was available in one case, while, apparent spontaneous ICH accounted for 6 of the remaining 23 cases (26%) occurring between the ages of 6 months to 5 years. Fourteen of 23 (60Á9%) cases in the 'no prophylaxis group' were clinically diagnosed as trauma-induced in children between the ages 3 months and 14 years. In three cases (13Á1%) in the 'no prophylaxis group' with a mild trauma it was not possible to distinguish whether the trauma caused the ICH, and no information was given in one case. In the 'full prophylaxis group', both reported cases of ICH were trauma-induced (2/2) occurring at ages 3 and 4 years. Of the three ICH's in the 'partial prophylaxis group' one (1/3) was trauma-related at the age of 14 years and two spontaneous bleeds were recorded (in patients aged 3 and 15 years). See Table III .
Symptoms
The most frequent symptoms of ICH were headache (13/29), lethargy (12/29) and vomiting (13/29). Less frequent symptoms were convulsions (3/29), coma (3/29), fever (2/29) and neurological symptoms, such as ataxia, aphasia and loss of appetite in one patient each.
Mortality
Two patients died due to ICH, the overall mortality in this cohort was 2 per 8038 patient years with a yearly incidence of 0Á025%. Overall mortality in patients with ICH -excluding neonatal and second ICH but including reported ICH in not yet diagnosed patients -was 2/44, resulting in 4Á5% mortality.
Sequelae
The median between date of ICH and report on sequelae was 34Á3 months (range 5Á68-80Á94). No sequelae were reported in patients with ICH in the full prophylaxis group (0/2) or the 'partial prophylaxis group' (0/3). Of the 24 ICH cases occurring in patients in the 'no prophylaxis group', two patients (8Á3%) died and 16 patients (16/24; 67%) had no sequelae. Of the patients with sequelae, eight patients (33%) had long-term sequelae: four patients had intellectual and behavioural problems (17%), three patients had paresis or other motor problems (13%), and one had epilepsy; some children had more than one adverse outcome. When comparing the follow-up time between the group with no sequelae (33Á90 months SD 20Á52) with those with sequelae (41Á77 months SD 24Á46), no statistical significance could be shown. 
Discussion
In this multicentre study, which included 1515 paediatric and young adult patients with severe haemophilia A and B from 33 haemophilia centres in 20 countries, full prophylaxis offered excellent protection against ICH while partial prophylaxis was found to be superior to no prophylaxis. Children in the 'full prophylaxis group', as defined above, had a risk of 0Á033 ICH/100 patient years compared to 0Á50 ICH/ 100 patient years for the 'partial prophylaxis group' and 1Á7 ICH/100 patient years for patients treated in the 'no prophylaxis group' (RR 50Á06 compared to 'full prophylaxis group' and 14Á92 compared to 'partial prophylaxis group'). The strength of our study is the large number of patients and the multicentre design, including the entire haemophilia population meeting the inclusion criteria at participating centres, providing a reliable denominator. Only minimal data were required in the CRF, making participation as simple as possible. The retrospective data had been collected routinely and continuously at annual comprehensive clinic visits at most participating centres, improving data reliability. In addition, ICH is such a serious event that it is unlikely to have been forgotten in a patient history spanning the previous 5 years. The prospective part of the study generated reliable data that was collected in real time. The subgroups 'full prophylaxis group', 'partial prophylaxis group' and 'no prophylaxis group' are clearly defined and make a direct comparison possible. The study population included centres worldwide treating some patients on no prophylaxis, enabling comparison of the 'full prophylaxis group' not only with published historical data but also to a concurrent comparator group.
Some of the strengths of the study are, at the same time, weaknesses. The electronic CRF was short, not enabling further analysis, e.g. on the exact date of switching treatment from one treatment group to another. We made further calculations regarding age under the assumption that ondemand treatment is followed by partial prophylaxis and full prophylaxis. The analysis shows a higher incidence for ICH in children treated on-demand over all age groups, which confirms our findings for the whole patient population. Further statistical analysis is not possible due to low numbers, but there was a tendency for a higher incidence for ICH between the age 1-3 years (13 ICH/444 patient years) treated on-demand compared to other age groups and compared to the partial and full prophylaxis groups, which had no ICH in that age group. In haemophilia, several studies have shown a higher risk for ICH in children, especially young children. In the French study (Stieltjes et al, 2005) , half of the ICH cases occurred in patients under 15 years of age. In an Italian study, ICH occurred at an incidence of 24Á4 per 1000 in the first year of age and 14Á9 per 1000 in the second year of age (Zanon et al, 2012) and in the study of Witmer et al (2011) , the median age of ICH was only 2 years. All these studies show a higher risk of ICH in the youngest children, most of who had not yet started prophylaxis. This emphasizes the need to start prophylaxis at an early age, possibly before the onset of clinical bleeding, to prevent ICH. While a randomised controlled trial determined that the risk of joint damage could be reduced 85% by starting full prophylaxis prior to age 30 months, there is still controversy regarding the optimal start age for each child. While clotting factor replacement would, ideally, commence as soon as haemophilia is diagnosed, practical issues including primarily venous access, limit factor replacement in the first year of life (Astermark et al, 1999; Ljung & Gretenkort Andersson, 2015; Nijdam et al, 2015) . In addition, 30% of patients with severe HA and 1-3% of those with severe HB develop inhibitory alloantibodies after a median of nine exposures to replacement factor (Gouw et al, 2007 (Gouw et al, , 2013 . The difficulties of care of a young infant who has developed an inhibitor, may hamper the early introduction of prophylaxis in neonates and very young infants at some centres. The current study supports that ICH incidence in the first years of life should be considered in decision making with regard to starting prophylaxis and time to achieve full prophylaxis.
Another issue is that the data collection could not measure adherence to the prescribed treatment. Treatment compliance is a well-known problem and previous studies have shown that adherence to treatment can be significantly lower than expected (Lindvall et al, 2006; Brand et al, 2015) . Insufficient adherence could have contributed to the cases of ICH in patients treated in the 'full prophylaxis group' even if they were reported as 'traumatic'. In our results, spontaneous intracranial bleeds were not seen in children on full prophylaxis. This supports the early hypothesis of Nilsson et al (1992) that prophylaxis twice weekly or more frequently could also prevent ICH.
One aim of the present study was to investigate the proportion of cases of ICH that were spontaneous, i.e. not related to trauma, and whether prophylaxis could reduce the risk of spontaneous ICH. In the 'no prophylaxis group', 26% of the ICH cases were spontaneous and none (0%; 0/2) occurred in the prophylaxis group. Because of the low number of cases of ICH in the prophylaxis groups, this question cannot be answered in this study. However, the data suggests that prophylaxis prevents most cases of ICH, regardless of injury history.
The evaluation of frequent symptoms of ICH included headache (44Á8%), vomiting (44Á8%) and lethargy (41Á3%), often in combination. Less frequent were convulsions (10Á3%) and coma (10Á3%) followed by various neurological symptoms. This is in agreement with other investigators: in a study by Andes et al (1984) , all patients with severe haemophilia had symptoms of ICH, such as apathy, tearfulness in young children and headache in older patients. Similarly, in an evaluation of 66 CT scans after paediatric head injury in patients with haemophilia and von Willebrand disease, vomiting was found in four of five patients and all five presented with an altered mental status and focal neurological deficit (Dietrich et al, 1994) . In contrast, in a study from the haemophilia centre in Philadelphia (Witmer et al, 2007 ) of a population with haemophilia who experienced head trauma, 295 CT-scans in 97 patients identified nine (3%) episodes of ICH, of whom 5/9 had no clinical signs or symptoms. In conclusion, we are currently not able to exclude ICH from symptoms alone; however, symptoms like headache, vomiting and lethargy and other neurological signs must be taken seriously and evaluated.
The overall mortality rate in this study was 4Á5% for patients with ICH after the neonatal period, confirming the findings of Witmer (2015) (2Á5%) that the mortality rate dropped significantly in the last decades when comparing to earlier studies. None of the patients with ICH in the 'full prophylaxis group' or 'partial prophylaxis group' had documented sequelae. Even 67% of patients of the 'on-demand group' were without sequelae but the remaining 33% had quite serious long-term sequelae, including death, epilepsy, intellectual and behavioural problems, and paresis or other motor problems causing many difficulties for these children and their families. The frequency and seriousness of sequelae may be underestimated because sequelae, such as intellectual problems, may be revealed later in life. One recent study from Italy underscores the difficulty in detecting sequelae accurately: Zanon et al (2014) reported that more patients than expected had mild cognitive dysfunction, hypothesized to be the result of micro-bleeds not reported as ICH. Following ICH, neuropsychological assessment should be routinely offered as follow-up.
In our study, FVIII and FIX treatment were given with conventional half-life concentrates. New treatment regimens with extended half-life products have subsequently been introduced and novel agents are on the horizon that may change treatment regimens for many patients (Berntorp & Andersson, 2016) . It is important that the ICH rate with conventional FVIII and FIX therapies is fully documented to be able to compare the ICH rate of new products with different pharmacokinetic options as applied to varying regimens. When discussing products with extended half-life, not only joint outcome but also other outcome measures, such as ICH, should be considered.
Conclusion
In this large paediatric multicentre study, ICH was shown to be a clinically significant and even fatal threat for children with severe haemophilia treated without prophylaxis therapy, while ICH was a rare event for patients treated prophylactically. Full prophylaxis was almost completely protective against ICH and was superior to no prophylaxis and partial prophylaxis. However, partial prophylaxis was superior to no prophylaxis treatment. Sequelae after ICH were only seen in patients treated with no prophylaxis therapy.
